Showing results (121-130 of 172) with videos related to
Sort By:
Pageof 18
Plos One|June 27, 2019
Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman diseaseChristopher S Nabel, Stephen Sameroff, Dustin Shilling, et al.Molecular Cancer Therapeutics|June 17, 2017
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt LymphomaLisa Giulino-Roth, Herman J van Besien, Tanner Dalton, et al.JCI Insight|September 9, 2021
Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individualsSabrina E Racine-Brzostek, Jim K Yee, Ashley Sukhu, et al.Nature|March 11, 2011
Inactivating mutations of acetyltransferase genes in B-cell lymphomaLaura Pasqualucci, David Dominguez-Sola, Annalisa Chiarenza, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial resultsJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.Cell Reports|January 7, 2014
Genetics of follicular lymphoma transformationLaura Pasqualucci, Hossein Khiabanian, Marco Fangazio, et al.Biorxiv : the Preprint Server for Biology|February 24, 2023
Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomasJie Li, Christopher R Chin, Hsia-Yuan Ying, et al.Frontiers in Oncology|September 16, 2021
Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AMLAmanda Lopez, Sanjay Patel, Julia T Geyer, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2009
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211Athe M N Tsibris, Roger Paredes, Amy Chadburn, et al.Blood|February 15, 2007
Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportinSara Gardenghi, Maria F Marongiu, Pedro Ramos, et al.Pageof 18